Jacobs Levy Equity Management’s Array Biopharma Inc ARRY Stock Holding History

Jacobs Levy Equity Management’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-82,909	Closed	-$1.26M	–	1115
2018 Q3	$1.26M	Buy	82,909 +15,349	+23%	+$235K	0.02%	613
2018 Q2	$1.13M	Sell	67,560 -20,200	-23%	-$321K	0.02%	635
2018 Q1	$1.43M	Buy	87,760 +37,900	+76%	+$607K	0.02%	553
2017 Q4	$638K	Buy	49,860 +27,400	+122%	+$312K	0.01%	710
2017 Q3	$276K	Buy	+22,460	New	+$209K	0.01%	804
2015 Q2	–	Sell	-27,500	Closed	-$203K	–	889
2015 Q1	$203K	Buy	+27,500	New	+$196K	﹤0.01%	701
2014 Q3	–	Sell	-75,700	Closed	-$345K	–	948
2014 Q2	$345K	Buy	+75,700	New	+$313K	0.01%	691
2013 Q3	–	Sell	-146,199	Closed	-$664K	–	1056
2013 Q2	$664K	Buy	+146,199	New	+$786K	0.01%	664

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Jacobs Levy Equity Management's ARRY Position: Q4 2018 in Review

Jacobs Levy Equity Management sold out of Array Biopharma Inc (ARRY) in Q4 2018, closing a stake of 82,909 shares — an estimated $1.26M sold.

Jacobs Levy Equity Management first reported a position in ARRY in Q2 2013 and held it in 8 quarters. The position peaked at $1.43M in Q1 2018. 236 funds tracked by Wall St. Rank hold ARRY as of Q4 2018.

Jacobs Levy Equity Management reported no remaining Array Biopharma Inc position as of Q4 2018 after selling out during the quarter.
Jacobs Levy Equity Management sold 82,909 Array Biopharma Inc shares in Q4 2018, an estimated $1.26M.
Jacobs Levy Equity Management first reported a position in Array Biopharma Inc in Q2 2013 and held it in 8 quarters.
Jacobs Levy Equity Management's Array Biopharma Inc position peaked at $1.43M in Q1 2018.
236 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2018.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2018, filed 14 Feb 2019.